Ampio (AMPE) Submits Pre-IND Package on Zertane to FDA

Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) has submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• Genworth Financial CEO returns from leave of absence in September
• James Hardie sells Fermacell unit to Holcim for €840 million